From coronary stents to defibrillators, and from pacemakers to devices that mask chronic pain, Boston Scientific aims to build the best possible medical solutions to support physicians and their patients. The company currently offers more than 13,000 products across 100-plus countries—and it's perpetually growing that portfolio by investing in both innovation and mergers and acquisitions (M&A). To support those ongoing research and development (R&D) and M&A investments, the treasury team is perpetually looking for ways to "fund the journey to fuel growth," as the company's strategy statement puts it.

Complete your profile to continue reading and get FREE access to Treasury & Risk, part of your ALM digital membership.

  • Critical Treasury & Risk information including in-depth analysis of treasury and finance best practices, case studies with corporate innovators, informative newsletters, educational webcasts and videos, and resources from industry leaders.
  • Exclusive discounts on ALM and Treasury & Risk events.
  • Access to other award-winning ALM websites including PropertyCasualty360.com and Law.com.
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Meg Waters

Meg Waters is the editor in chief of Treasury & Risk. She is the former editor in chief of BPM Magazine and the former managing editor of Business Finance.